Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation-Reference-Cited by-同舟云学术

Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation

Published:2018-09-24 Issue:1 Volume:109 Page:98-106
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Yamasaki Satoshi, ,Yoshimoto Goichi,Kohno Kentaro,Henzan Hideho,Aoki Takatoshi,Tanimoto Kazuki,Sugio Yasuhiro,Muta Tsuyoshi,Kamimura Tomohiko,Ohno Yuju,Ogawa Ryosuke,Eto Tetsuya,Nagafuji Koji,Miyamoto Toshihiro,Akashi Koichi,Iwasaki Hiromi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-018-2538-8/fulltext.html

Reference31 articles.

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

2. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28:830–4.

3. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003;4:293–304.

4. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

5. Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, et al. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med. 2013;52:63–70.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies: Insights from a Chinese single-center experience (1997–2021);Cancer Pathogenesis and Therapy;2024-06

2. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs;Haematologica;2023-07-20

3. An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma;Recent Updates on Multiple Myeloma;2023-03-15

4. Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018;Cancers;2022-10-07

5. Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016;Annals of Hematology;2022-09-13